Undisclosed Small Molecule

About Aquinnah Pharmaceuticals

Aquinnah Pharmaceuticals is a private, preclinical-stage biotech targeting the root cause of neurodegenerative diseases through a novel mechanism involving pathological biomolecular condensates. The company's platform, born from the seminal discovery of the stress granule-disease connection by its CSO, aims to develop oral small molecules that could halt disease progression in ALS and Alzheimer's. With a seasoned leadership team, validation from major pharma partnerships, and compelling preclinical data showing ~70% reduction in tau pathology, Aquinnah is positioning itself as a potential disruptor in a field with immense unmet need. Its progress is supported by peer-reviewed grants and strategic industry collaborations.

About Aquinnah Pharmaceuticals

Aquinnah Pharmaceuticals is a private, preclinical-stage biotech targeting the root cause of neurodegenerative diseases through a novel mechanism involving pathological biomolecular condensates. The company's platform, born from the seminal discovery of the stress granule-disease connection by its CSO, aims to develop oral small molecules that could halt disease progression in ALS and Alzheimer's. With a seasoned leadership team, validation from major pharma partnerships, and compelling preclinical data showing ~70% reduction in tau pathology, Aquinnah is positioning itself as a potential disruptor in a field with immense unmet need. Its progress is supported by peer-reviewed grants and strategic industry collaborations.

Therapeutic Areas

Other Alzheimer's Disease Drugs